Arch Therapeutics Inc (ARTH)

[Cosmic Chi]

If I remember correctly, they're doing an external trial using dermatology patients undergoing skin lesion removal. Patients are having 2 or more lesions removed with the wounds treated with AC5 and a normal haemostatic agent - with this approach you not only get to see the efficacy of AC5 on humans but you can also compare the results against a standard haemostatic agent (remembering that these trials are the first on humans, all other tests have been on animals).

It would be more difficult to compare the two methods if you were using internal surgical procedures. For me this trial is about safety, effectiveness and the benefits of using AC5 rather than other agents.

Other external applications on burns, ulcers etc would be the next logical move followed at some point in the future with internal surgical applications.

Please correct me if I'm wrong on this - this is just from what I remember reading in previous posts...

Per Ardua Ad Astra